Fatty Liver Disease: Woman’s Life Saved by Weight Loss Drug Mounjaro
- For 55-year-old Belinda Whitlock, repeated visits to her general practitioner for fatigue, nausea, and unexplained stomach pain initially led to a diagnosis of menopause.
- Fatty liver disease, affecting up to one in five adults, is often linked to obesity and long-term inflammation.
- Belinda initially adopted a Mediterranean diet, increased her coffee intake, and eliminated takeaways.
For 55-year-old Belinda Whitlock, repeated visits to her general practitioner for fatigue, nausea, and unexplained stomach pain initially led to a diagnosis of menopause. Despite being prescribed hormone replacement therapy (HRT), her symptoms persisted. A fortunate turn of events – a sonographer examining her abdomen during an ultrasound intended for a different purpose – revealed signs of a fatty liver. Further testing confirmed advanced liver fibrosis, a condition where scarring impedes the liver’s function.
Fatty liver disease, affecting up to one in five adults, is often linked to obesity and long-term inflammation. Belinda recalls the diagnosis as “hitting me like a sledgehammer,” particularly given her mother’s death from liver cancer at age 46. She feared a similar fate and worried about the impact on her four children.
Belinda initially adopted a Mediterranean diet, increased her coffee intake, and eliminated takeaways. After seven months, she had lost two stone, but scans showed limited improvement in her liver condition. Seeking further options, she began a private prescription for the weight-loss drug Mounjaro in August 2024, paying hundreds of pounds monthly. Since then, she has lost an additional five stone, and recent scans indicate her liver fibrosis is reversing.
Belinda’s experience highlights a growing recognition of the potential for GLP-1 drugs, like Mounjaro, to address liver disease. Professor Philip Newsome, a liver expert at King’s College London, notes that the rise in liver disease is “alarming” and that the use of weight-loss drugs to treat the condition is “really promising.” He emphasizes that research now suggests these drugs can help reverse liver damage, something previously considered impossible.
The increase in fatty liver disease cases is largely attributed to poor diets and sedentary lifestyles. The condition progresses through stages, beginning with excess fat accumulation, potentially leading to inflammation and scarring. The British Liver Trust estimates that 80% of individuals with fatty liver disease remain undiagnosed, often due to the absence of early symptoms. If left untreated, it can progress to cirrhosis, a non-reversible condition without liver transplantation.
Cirrhosis represents end-stage liver disease, where the liver loses its ability to filter toxins from the blood. Symptoms can include jaundice, fatigue, abdominal pain, intense itching, and swelling. Professor Newsome explains that the traditional view was that scarring was irreversible, but “if you treat the underlying cause of liver damage, you can see remarkable remodelling of scar tissue.” While a return to a completely normal liver may not be achievable, improvement to a less harmful state is possible.
Gillian Scott, a 57-year-old civil servant, experienced a similar positive outcome with Mounjaro. Diagnosed with cirrhosis in 2023 following years of poorly controlled type 2 diabetes and obesity, her diabetes nurse switched her treatment to Mounjaro in June 2024. She has since lost nine stone, and scans show her condition has improved from cirrhosis to fibrosis.
Research supports the use of weight-loss drugs for liver disease. A study published in the New England Journal of Medicine found that 62% of patients taking the highest maintenance dose of Mounjaro (15mg) achieved complete resolution of fatty liver disease, with liver function returning to normal. Professor Newsome suggests these drugs may have benefits beyond weight loss and blood-sugar control, potentially exerting a direct effect on immune cells in the liver, though the exact mechanisms are still being investigated.
Currently, GLP-1 drugs are not yet approved by the National Health Service (NHS) in the UK for the treatment of liver disease, though a decision is anticipated this summer. This delay poses a financial burden for patients like Belinda, who have been funding their prescriptions privately, sometimes requiring assistance from family members.
The availability of medications like Mounjaro represents a significant development in the management of fatty liver disease. While weight loss has long been recognized as the most effective treatment, these newer drugs offer a potentially more targeted and impactful approach. However, it’s important to remember that these medications are prescription-only and should be used under the guidance of a healthcare professional. Further research is ongoing to fully understand the long-term effects and optimal use of these drugs in treating liver disease.
The Fatty Liver Foundation provides resources and information for patients dealing with fatty liver disease, including details on Rezdiffra, Wegovy, and Mounjaro. These three medications, available as of the end of , represent different approaches to managing the condition: Resmetirom (Rezdiffra) targets the liver directly, while Semaglutide (Wegovy) and Tirzepatide (Mounjaro) focus on weight loss outside the liver.